Ethiodized Oil Uptake Does Not Predict Doxorubicin Drug Delivery after Chemoembolization in VX2 Liver Tumors

Gaba, Ron C.; Baumgarten, Sigrid; Omene, Benedictta O.; Breemen, Richard B. van; García, Kelly; Larson, Andrew C.; Omary, Reed A.

doi:10.1016/j.jvir.2011.10.022

Cited by 39 publications

(32 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Specifically, the advantages of higher response rates in high-risk patients, lower hepatic and with positively charged moieties in drugs such as doxorubicin by an ion-exchange mechanism and allow loading of the drug from dilute solutions. Use of drug-eluting microspheres for TACE leads to high and sustained intratumoral doxorubicin concentrations, as well as decreased systemic drug levels and toxicity (3)(4)(5)(6)(7)(8).…”

Section: Vascular and Interventional Radiologymentioning

confidence: 99%

Superselective Chemoembolization of HCC: Comparison of Short-term Safety and Efficacy between Drug-eluting LC Beads, QuadraSpheres, and Conventional Ethiodized Oil Emulsion

Duan¹,

Wang²,

Lam³

et al. 2016

Radiology

View full text Add to dashboard Cite

q RSNA, 2015 Purpose:To study the comparative short-term safety and efficacy of transcatheter arterial chemoembolization (TACE) with drugeluting LC Beads loaded with doxorubicin (DEBDOX), doxorubicin-eluting QuadraSpheres (hqTACE), and conventional TACE using ethiodized oil for superselective C-arm computed tomography (CT)-guided treatment of hepatocellular carcinoma (HCC) after the onset of drug shortages. Materials and Methods:From March 2010 to March 2011, 166 patients with HCC were treated with 232 superselective TACE procedures using C-arm cone-beam CT at one institution. Patients underwent treatment depending on the availability of materials after the onset of drug shortages. Conventional TACE with doxorubicin, cisplatin, and Ethiodol was performed for 159 procedures, DEBDOX TACE was performed for 47, and hqTACE was performed for 26. Toxicity and objective response were compared at 3 months after treatment. Data were stratified for the high-risk population (Child-Pugh class B, performance status 1, bilobar disease, and/or postresection recurrence) and initial versus repeat treatment. Kruskal-Wallis H test, Mann-Whitney U test, and Fisher exact test were used to compare the groups, with Bonferroni correction where needed. Results:Whole liver response rates trended higher for conventional TACE (conventional TACE, 65.4%; DEBDOX, 63.8%; hqTACE, 53.8%) (P = .085). Only minor trends for differences in toxicity were observed between the three groups. Low-risk patients had higher whole liver (P = .001) and treated lesion (P = .007) response rates when treated with conventional TACE, but no significant differences were seen for DEBDOX and hqTACE. Treatment-naive patients also had higher whole liver (P = .012) and treated lesion (P = .056) response rates. No advantages for drug-eluting microspheres were found. Conclusion:Within statistical power limitations, overall toxicity and efficacy were equivalent in patients treated with LC Beads, QuadraSpheres, or ethiodized oil emulsions, including in high-risk patients, when performed superselectively with cone-beam C-arm CT guidance.q RSNA, 2015

show abstract

Section: Vascular and Interventional Radiologymentioning

confidence: 99%

Superselective Chemoembolization of HCC: Comparison of Short-term Safety and Efficacy between Drug-eluting LC Beads, QuadraSpheres, and Conventional Ethiodized Oil Emulsion

Duan¹,

Wang²,

Lam³

et al. 2016

Radiology

View full text Add to dashboard Cite

show abstract

“…Development and propagation of the VX2 cell line was performed according to previously described methodology (11). Briefly, flash-frozen rabbit VX2 tumor samples (0.75-1 mL, approximately 10 7 cells) were defrosted, mixed in methylcellulose media (Stemcell Technologies) in a 1:1 ratio, and injected into the hind limb muscle of donor New Zealand white rabbits for propagation.…”

Section: Rabbit Vx2 Tumor Development and Propagationmentioning

confidence: 99%

“…After the procedure, the animals were aroused and recovered, returned to cages, and monitored daily for wound healing and appetite until TACE. Liver tumors were incubated for three weeks prior to TACE based on previous experience of suitable 2-3 cm diameter tumor growth within 14-28 days (11).…”

Section: Vx2 Liver Tumor Implantationmentioning

confidence: 99%

Pharmacokinetic study of conventional sorafenib chemoembolization in a rabbit VX2 liver tumor model

Parvinian¹,

Casadaban²,

Hauck³

et al. 2015

Diagn Interv Radiol

Self Cite

View full text Add to dashboard Cite

“…Because the use of Ethiodol does not result in permanent arterial occlusion, this contrast medium is not considered an embolic agent in the strict sense, but is rather intended for carrying and temporarily localizing chemotherapeutic agents inside a tumor. Indeed, several authors have shown that, even though Ethiodol is intended to carry chemotherapeutic agents, Ethiodol and chemotherapeutic drugs do not end up in the same place in the tumor (5).…”

mentioning

confidence: 99%

Degradable Starch Microspheres versus Ethiodol and Doxorubicin in Transarterial Chemoembolization of Hepatocellular Carcinoma

Niessen

Unterpaintner

Goessmann

et al. 2014

Journal of Vascular and Interventional Radiology

View full text Add to dashboard Cite

Ethiodized Oil Uptake Does Not Predict Doxorubicin Drug Delivery after Chemoembolization in VX2 Liver Tumors

Cited by 39 publications

References 35 publications

Superselective Chemoembolization of HCC: Comparison of Short-term Safety and Efficacy between Drug-eluting LC Beads, QuadraSpheres, and Conventional Ethiodized Oil Emulsion

Superselective Chemoembolization of HCC: Comparison of Short-term Safety and Efficacy between Drug-eluting LC Beads, QuadraSpheres, and Conventional Ethiodized Oil Emulsion

Pharmacokinetic study of conventional sorafenib chemoembolization in a rabbit VX2 liver tumor model

Degradable Starch Microspheres versus Ethiodol and Doxorubicin in Transarterial Chemoembolization of Hepatocellular Carcinoma

Contact Info

Product

Resources

About